Summit Therapeutics Inc. (SMMT): Management meeting at ESMO frames the Phase 3 biliary tract cancer win and broader ivo outlook

At the ESMO Congress, we hosted a dinner with SMMT management following partner Akeso's Presidential Session Phase 3 HARMONi-GI1 (China-only) presentation in frontline biliary tract cancer. Key takeaways: ivonescimab plus chemotherapy demonstrated clear, clinically meaningful superiority over Imfinzi plus chemotherapy, the current standard of care, with an overall survival hazard ratio of 0.75 (p=0.0031), median OS of 14.9 vs. 12.1 months, PFS HR of 0.61 (8.4 vs. 5.8 months), and confirmed ORR of 53.8% vs. 32.5%, with manageable safety. The data mark ivonescimab's first Phase 3 win beyond NSCLC, support the recently announced registration-enabling Phase 2/3 EA2251 study in BTC with ECOG-ACRIN, and underpin the broader GI and RCC development strategy. Management positions ivonescimab as a foundational next-generation IO backbone, pursuing novel/novel combinations with ADCs and other agents. Focus remains on the global Phase 3 HARMONi-3 study in frontline NSCLC, with events triggering th